Innate Pharma Schedules Q1 2025 Business Update Conference Call

Innate Pharma SA ( (FR:IPH) ) has shared an announcement.

On May 6, 2025, Innate Pharma announced a conference call scheduled for May 13, 2025, to provide a business update for the first quarter of 2025. The event will feature key executives and will be followed by meetings with investors in New York and Boston. This initiative reflects Innate Pharma’s ongoing efforts to engage with stakeholders and provide transparency regarding its operations and strategic direction.

More about Innate Pharma SA

Innate Pharma S.A. is a global, clinical-stage biotechnology company focused on developing immunotherapies for cancer patients. The company leverages its proprietary ANKET® platform to create multi-specific NK Cell Engagers, along with developing Antibody Drug Conjugates and monoclonal antibodies. Innate Pharma collaborates with biopharmaceutical companies like Sanofi and AstraZeneca to advance research and development, with its headquarters in Marseille, France, and a US office in Rockville, MD.

YTD Price Performance: -50.0%

Average Trading Volume: 1,075

Technical Sentiment Signal: Buy

Current Market Cap: $186.3M

For detailed information about IPH stock, go to TipRanks’ Stock Analysis page.